Supernus' depression treatment fails mid-stage trial, shares plunge (updated)

Supernus Pharmaceuticals

18/02/2025 21:49

(Adds trial details in paragraphs 2,3 and CEO comment in
paragraph 4)
       Feb 18 (Reuters) - Supernus Pharmaceuticals  SUPN.O 
said on Tuesday its depression treatment trial failed to meet
the main goal of reduction in depressive symptoms, sending its
shares down 22% aftermarket.
    The company said the drug, SPN-820, did not show a
statistically significant change compared to placebo when tested
in 250 patients with treatment-resistant depression during a
mid-stage trial.
    The patients were tested with the Montgomery-Asberg
Depression Rating Scale, which measures severity of various
symptoms of depression such as sadness, inner tension, reduced
sleep and inability to feel.
    "We will continue to analyze these data and discuss the
future of the program with our development partner, Navitor
Pharmaceuticals," said Supernus CEO Jack Khattar.
   
    

 (Reporting by Christy Santhosh in Bengaluru; Editing by Alan
Barona)
 ((Christy.Santhosh@thomsonreuters.com))